Reported about 7 hours ago
Eli Lilly's stock has sharply fallen following a decrease in its 2024 revenue forecast, raising concerns over demand for its weight-loss drugs. The stock broke below key technical levels, signaling potential further decline, with investors advised to monitor support at $720 and $625, as well as resistance levels at $860 and $965.
Source: YAHOO